Background and Purpose Although oral antithrombotic therapy (OAT) is a risk factor of intracerebral hemorrhage (ICH), the clinical course of supratentorial ICH with prior OAT is unclear. We therefore assessed the characteristics of supratentorial ICH with OAT to determine whether OAT is independently associated with early death in supratentorial ICH.
Introduction
Spontaneous intracerebral hemorrhage (ICH) is associated with a poor functional outcome of stroke, and the mortality rate of ICH is high (1) . Although the use of intravenous thrombolysis for ischemic stroke had already been established (2), effective medical treatment for ICH is only now being developed (3) .
Prior oral antiplatelet and oral anticoagulant (oral antithrombotic therapy: OAT) are risk factors for ICH (4) .
istics of supratentorial ICH with OAT (13) , and the characteristics of supratentorial ICH with prior OAT are still unclear.
The aim of this study was therefore to clarify the background of supratentorial ICH with prior OAT, and to determine whether OAT is independently associated with early death in supratentorial ICH.
Subjects and Methods

Inclusion and exclusion criteria
We retrospectively enrolled consecutive patients with supratentorial intracerebral hemorrhage (ICH) admitted to the Stroke Center of Kawasaki Medical School Hospital within 24 hours of onset from April 2004 to March 2009. Traumatic ICH, vascular malformation, tumor, Moyamoya disease, hematologic disease, and pregnant and pediatric patients were excluded.
Risk factors and oral antithrombotic therapy
We obtained risk factors and past history including the following: hypertension, diabetes mellitus, hyperlipidemia, atrial fibrillation, hemodialysis, hepatic disease, oral antithrombotic therapy (OAT), alcohol consumption, smoking, transient ischemic attack (TIA), ischemic stroke, ICH, acute coronary syndrome (ACS), and arteriosclerosis obliterans (ASO). All patients or their family answered questions about their past history, medications, smoking status, alcohol consumption, and activities of daily living (ADL). ADL before onset were evaluated using the modified Rankin scale (mRS) (14) . When mRS was 4 or 5, the patient was considered dependent. We defined OAT as previous use of any OAT (antiplatelet: aspirin, ticlopidine, clopidogrel, cilostazol, or anticoagulant: warfarin potassium) (15) . We documented single or dual use of antiplatelet agents and the use of antiplatelet plus anticoagulant agents (16) . We also investigated indications for OAT.
Risk factors were identified as follows (17): 1. hypertension patient's or family's report of HT or systolic blood pressure (BP) >140/diastolic BP >90 mmHg at health check before onset (18) or use of antihypertensive agents; 2. diabetes mellitus having ever been diagnosed with diabetes mellitus at health check or at a hospital by criteria at that time (fasting blood glucose level >126 mg/dL, or random blood glucose level >200 mg/dL, and among others) (19) , or the use of oral antidiabetic medication or insulin; 3. hyperlipidemia use of antihyperlipidemic agents or serum total cholesterol >220 mg/dL and/or fasting serum triglyceride >150 mg/dL; 4. smoking any lifetime experience with cigarette use; 5. atrial fibrillation detection on electrocardiogram in emergency room or documented formerly; 6. hemodialysis undergoing hemodialysis regularly (20); 7. acute coronary syndrome (ACS) symptomatic angina pectoris or myocardial infarction treated in hospital. 8. hepatic diseases hepatitis and/or liver cirrhosis (21) . We also recorded the history of symptomatic transient ischemic attack (TIA), ischemic stroke, ICH, ACS, and ASO.
Neuroimaging
We performed cranial CT scans at admission (within 24 hours of onset) for all patients. All cranial CT scans were performed according to the Radiology Department protocol, with an image matrix of 340×340 and a slice width of 8-10 mm. Investigators who read the CT scans were blind to clinical information. The location, volume of hematoma, the presence of ventricular bleeding, and the time interval from ICH onset to CT scanning were documented. The volume of hematoma was measured by the ABC/2 method (22). We determined hematoma expansion when CT scan was repeated within 24 hours of the baseline CT scan. A greater than 33% increase in volume between two CTs was considered hematoma enlargement.
Physical findings and outcome
We measured systolic and diastolic blood pressure at arrival to our hospital. We also assessed neurological condition and level of consciousness using the Glasgow Coma Scale (GCS) score (11, 23) . All surgical treatments were performed according to the guidelines (24, 25) and were recorded as operations (hematoma evacuation or ventricular drainage). We defined early death as death within 14 days of onset. We also evaluated the cause of death by the medical chart and based on the result of autopsy when performed.
Laboratory data
We drew blood samples from all patients in the emergency room prior to CT scan. The white blood cell (WBC) count, platelet count, blood glucose, total cholesterol, serum albumin, C reactive protein (CRP), and prothrombin timeinternational normalized ratio (PT-INR) were examined (26) .
Statistical analysis
We compared characteristics of the group with oral antithrombotic therapy (OA group) and that without it (non-OA group), to clarify the characteristics of the group with OAT. In cases of early death, we also distinguished between causes of death in the OA group and those in the non-OA group. The significance of inter-group differences was assessed by Fisher's exact test or the chi-square test for categorical variables and Mann-Whitney U test for continuous and ordinal variables, respectively. To determine the 14-day survival rate, we constructed Kaplan-Meier survival curves for the OA group and non-OA group, and used the log-rank test to determine the significance of survival characteristics between them. We also estimated number at risk in each group, the age-and sex-adjusted hazard ratio (HR) of OAT for death, and HR adjusted for age, sex, GCS and volume of hematoma, at days 1, 3, 7, and 14. To identify independent predictors of early death, we used an age-and sex-adjusted Cox proportional hazards model for death within 14 days, and estimated the hazard ratios (HR) of variables. When Table 1 . Baseline Characteristics and Hematoma Location for All Groups, Including the Group with Oral Antithrombotics (OA Group) and the Group without (no OA Group) variables featured p<0.1 and variables were not associated OAT, the cut-off points for each continuous and ordinal variable for predicting early death were determined using receiver operating characteristic (ROC) curves. In the multivariable Cox regression analysis, age, sex, and variables showing p<0.1 on age-and sex-adjusted Cox hazards model for early death were included. For OAT, we also estimated HR in several models: 1. unadjusted, 2. age-and sex-adjusted, 3. Model A: adjusted for age, sex, and risk factors and laboratory data which showing p<0.1 on age and sex adjusted Cox hazard model, 4. Model B: adjusted for age, sex, Glasgow coma scale, volume of hematoma, and ventricular bleeding (known predictors of death in ICH). 5. Model C: adjusted for glucose (26) and Model B. Statistical analysis was performed with PASW statistics ver. 17.2 (SPSS Inc., Chicago, IL, USA).
The study protocol followed the principles outlined in the Declaration of Helsinki, and was approved by the Medical Ethics Committee of the Kawasaki Medical School.
Results
A total of 389 patients with supratentorial ICH [median age 68 years (59-77), 239 (61%) males] were enrolled in the present study. The locations of hematoma were: the putamen in 148 cases (38%), thalamus in 149 (38%), lobar in 40 (10%), combined in 43 (11%), and caudate in 9 (2.3%) (Table 1). Oral antithrombotic treatments were used in 94 (24%) patients (OA group). In the OA group, only warfarin potassium was used in 10 (11%) cases, single antiplatelet agent in 63 (67%), dual antiplatelet agents in 10 (11%), and antiplatelet plus warfarin potassium in 11 cases (11%). Seventy-three patients were treated with antiplatelet agents before occurrence of cerebral hemorrhage. Aspirin was used in 68 cases (93%), cilostazol in 4 (5.4%), ticlopidine in 15 (21%), and clopidogrel in 3 (4.1%). Table 1 also shows the baseline characteristics of the OA and non-OA groups. Indications for OAT in the OA group included, ischemic stroke or TIA in 50 cases (53%), arterial fibrillation 13 (13%), ACS 15 (16%), and ASO 4 (4%). Each of these diseases was more frequently observed in the OA than in the non-OA group (Table 1) . While 60 (64%) patients in the OA group had one disease as the indication, and 10 (11%) patients had two or three diseases as an indication, 24 (25%) patients had no disease as an indication for treatment.
The OA group was older than the non-OA group (median 74 years, OA group vs. 66 years, non-OA group, p<0.001). The OA group had a larger proportion of males (72% vs. 58%, p=0.013), and patients with hypertension (87% vs. 69%, p<0.001), diabetes mellitus (31% vs. 18%, p<0.001), and use of hemodialysis (14% vs. 3%, p<0.001). Table 2 shows vital signs, CT findings, outcome, and laboratory data. GCS was lower in the OA group than in the non-OA group (median 10 [25th-75th percentile: 5-14] vs., 13 [10] [11] [12] [13] [14] [15] , p<0.001). The OA group had larger hematoma [median 22 mL (25th-75th percentile: 7.2-100 mL), vs. median 14 mL (7-42 mL), p<0.001]. In addition ventricular bleeding was more frequently observed in the OA group (75% vs. 59%, p=0.008). Among laboratory findings, total cholesterol 4 .2 g/dL (3.9-4.4 g/ dL), p<0.001] were less than those in the non-OA group. Early death was more frequent in the OA group (28% vs. 8%, p<0.001). The frequency of early death was 60.0% (6/ 10) in warfarin potassium group, 38.0% (24/63) in single antiplatelet therapy, 30.0% (3/10) in dual antiplatelet therapy and 45.5% (5/11) in antiplatelet and warfarin potassium (p= 0.10 chi-square test). Therefore, there were no significant differences in the frequency of early death among the four groups. Herniation and/or hydrocephalus due to ICH were the main causes of early death in both groups with no significant difference between them (p=0.189, chi-square test). However, hematoma expansion and stopping hemodialysis due to poor physical condition were more frequently observed in the OA group. On the other hand, ACS and embolism of atrial thrombus were only in the non-OA group.
On Kaplan-Meier curve analysis, the survival rate curve for the OA group was significant lower than that for non-OA group (p for log-rank test <0.001) (Fig. 1) . Number at risk, HR of OAT for death adjusted for age and sex, and HR adjusted for age, sex, GCS, and hematoma volume are shown at the bottom of Fig. 1 . HR adjusted for age and sex at day 1 was 5.81 (p=0.69), day 3: 4.80 (p<0.01), day 7: 4.11 (p<0.01), and day 14: 3.62 (p<0.01). HR adjusted for age, sex, GCS, and hematoma volume (model 1) at day 1 was 2.63 (p=0.34), day 3: 2.35 (p=0.03), day 7: 2.01 (p= 0.04), and day 14: 1.90 (p=0.04). HR adjusted for age and sex, and HR adjusted model 1 became significant after day 3 and then decreased slowly.
For multivariable Cox regression analysis, we estimated cut-off levels for prediction of early death using ROC curve analysis. Cut-off levels for prediction of early death with high sensitivity and high specificity were: GCS <9 (sensitivity, 80% and specificity, 84%), volume of hematoma >55 mL (82% and 83%), WBC >8,500 (64% and 68%), and glucose >160 mg/dL (76% and 71%). Table 3 shows HR adjusted for age and sex for each variable. The use of OAT, GCS <9, volume of hematoma >55 mL, and the presence of ventricular bleeding were associated with early death. Among laboratory findings, WBC >8,500 and glucose >160 mg/dL were also associated with early death. Higher PT-INR was associated with early death. In the patients treated with warfarin potassium, however, there were no differences in PT-INR between the early death group and the survivals group [2.49, (1.57-3.32) vs. 2.27 (2.00-2.77), p=0.972]. We included age, sex, OAT, GCS <9, volume of hematoma >55 mL, ventricular bleeding, WBC >8,500, and glucose >160 mg/dL, in the multivariable Cox regression analysis. We excluded atrial fibrillation, hemodialysis, past history of ischemic stroke, ACS, ASO, and PT-INR from this analysis, since they were associated with oral antithrombotic treatment (Table 1, 2) . On this multivariable analysis, OAT (HR 2.01, 95% CI 1.11-3.65, p=0.022), GCS <9 (HR 2.93, 95% CI 1.28-6.73, p=0.011), volume of hematoma >55 mL (HR 5.19, 95% CI 2.26-11.9, p<0.001), and glucose >160 mg/dL (HR 2.58, 95% CI 1.22-5.43, p=0.013) were independent predictors of early death (Table 4) . We used several models for estimating HR of OAT. Unadjusted HR was 3.62 (95% CI 2.06-6.33, p<0.001), HR adjusted for age, sex, WBC > 8,500, and glucose >160 mg/dL (model A) was 3.15 (95% CI 1.74-5.70, p<0.001). Among known predictors, HR adjusted for model B was 1.93 (95% CI 1.05-3.54, p=0.033), and HR adjusted for model C was 2.01 (95% CI 1.11-3.65, p=0.022) ( Table 5) . Prior OAT was a predictor of early death in several models.
Discussion
Of patients with supratentorial ICH, 24% were taking OAT prior to its onset. Although 75% of patients in the OA group had an indication for OAT, the remainder did not. The OA group was older than the non-OA group. Early death was more frequently observed in the OA group. OAT was independently associated with early death in patients with supratentorial ICH.
We also found that age was not associated with the early death. This finding is not consistent with a previous report stating that age was associated with early death in supratentorial ICH (11) . There may be two reasons for this discrepancy in findings. First, elderly patients tended to undergo OAT in the present study. Second, the previous study did not include examination of OAT.
The OA group had a poor neurological status, and supratentorial ICH with prior OAT was associated with a large volume of hematoma in the present study. The most common location of hematoma was the thalamus in the OA group, and putaminal hemorrhage was less than in non OA group. This phenomenon was similar to previous studies (12, 27) . In the OA group, thalamus or basal ganglia were the common location of supratentorial hemor- (15) . Toyoda et al also demonstrated a strong relationship between OAT and death within 3 weeks for all types of ICH (15) . Their population included all types of ICH, while that of the present study was limited to patients with supratentorial ICH. Thus, although the populations examined differed between in the study of Toyoda et al and in the present study, a similar relationship between OAT and early death in ICH was observed. Previously, low GCS and large volume of hematoma were predictors of death in supratentorial ICH (11) . Indeed when predictors were also included in the multivariate analysis, OAT was strongly associated with early death. Some factors correlate with OAT and early death, and could affect the survival rate and HR.
We determined HRs of OAT for death over several days. Both HR adjusted for age and sex, and that adjusted for model 1 became significant after day 3. No previous studies presented the course of change in HR for OAT in ICH. Hematoma expansion may be related to the increase in HR for OAT in ICH, since it was a cause of death only in the OA group, and tended to occur in patients with OAT (15) . The disturbance of HD also plays a role in the relationship of OAT to early death, for the same reason. If all patients with early death were to undergo autopsy, the nature of the relationship between OAT and early death could be determined.
Prior to the onset of supratentorial ICH onset, 24% of patients were undergoing OAT. Six percent of patients with supratentorial ICH (25% of the OA group) were administered OAT inappropriate. Our findings are consistent with the report of Toyoda et al in that 27% of all ICH patients were undergoing OAT (15) . However, a few reports have described the indications for use of OAT (13, 28) . Neau et al demonstrated that all patients were indicated for the use of anticoagulant (28) . However, Roquer et al found that 11% of patients in their series were not indicated for anticoagulant (13) . Some patients taking OAT were not indicated for it in the series of Roquer et al and our own. Indeed, few clear data are available concerning the reasons for use of antiplatelet agents, though some physicians tend to use them for asymptomatic stroke or mild arteriosclerosis. Since OAT is also a risk factor for ICH (9, 16, 29, 30) , it is necessary to administer OAT should with care.
There are several limitations to this study. First, this study was retrospectively performed at a single center. However, examination of the details of OAT was simple to perform in a single center. Second, we did not evaluate hematoma expansion, since some patients did not undergo follow-up CT scan due to poor status, and we could not control the time between the first and second CT scans. If CT could be performed on day 2 for all surviving patients, the reason as to why the HR of OAT for death became significant after day 3 could be determined.
In conclusion, prior oral antithrombotic therapy was associated with early death in patients with supratentorial ICH. Decreasing the incidence and mortality of ICH, thus requires appropriate use of this therapy.
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